Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators

The American Journal of Cardiology
P LarochelleR A Reeves

Abstract

In this double-blind, randomized study, an antihypertensive regimen based on irbesartan, an angiotensin II receptor antagonist, reduced systolic and diastolic blood pressure by 40/30 mm Hg at week 12 in patients with severe hypertension; this reduction was at least equivalent to that of a regimen using enalapril up to 40 mg. The irbesartan-based regimen had a better tolerability profile with fewer adverse events (55% vs 64%) and significantly less cough (2.5% vs 13.1%, p = 0.007).

Citations

Mar 25, 2004·Clinical Therapeutics·Francisco J Morales-OlivasUNKNOWN KARTAN Study Investigators
Mar 20, 2003·Current Diabetes Reports·Kambiz Kalantarinia, Helmy M Siragy
Jun 6, 2009·Current Diabetes Reports·Amgad N MakaryusSamy I McFarlane
Jan 1, 2010·Integrated Blood Pressure Control·Giuseppe Derosa, Sibilla At Salvadeo
Sep 29, 2011·Integrated Blood Pressure Control·Valentina ForniMichel Burnier
Oct 15, 2013·Vascular Health and Risk Management·Fotini Gialama, Nikos Maniadakis
Feb 15, 2005·International Journal of Clinical Practice·C-C ChouM-H Chuang
Apr 23, 1999·Pharmacotherapy·D A Sica, N K Hollenberg
Mar 12, 2004·Expert Opinion on Pharmacotherapy·Steven G Chrysant, George S Chrysant
Jul 5, 2005·Expert Opinion on Investigational Drugs·C I Johnston
Jun 26, 2010·Diabetology & Metabolic Syndrome·Sanjay KalraNavneet Agrawal
Feb 15, 2001·Circulation·M Burnier
Feb 14, 2003·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Domenic A Sica, Todd W B Gehr
Sep 14, 2002·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Jun R Chiong, Alan B Miller
Jan 22, 2018·Clinical Pharmacokinetics·Yash GandhiTushar Garimella
Jun 1, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·D A SicaA Fernandez
Jun 3, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M R GreenM J Hawkins
Mar 3, 2007·Pharmacy World & Science : PWS·Waleed M Sweileh
Mar 26, 2014·Cancer Chemotherapy and Pharmacology·John F DeekenPatricia M LoRusso
Jul 23, 2013·HSS Journal : the Musculoskeletal Journal of Hospital for Special Surgery·Susan M GoodmanStavros Memtsoudis
Aug 11, 2019·Liver International : Official Journal of the International Association for the Study of the Liver·Yu-Yun ShaoChih-Hung Hsu
Nov 5, 2003·Blood Pressure·Lindon M H WingDanielle Molloy
Jul 16, 2009·Expert Opinion on Pharmacotherapy·Peter BramlageCaroline Hacker
Jun 1, 2011·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Mohamed A El-HaddadSony Jacob

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.